Artelo Biosciences files provisional patent for ART27.13 obesity use after mouse study shows up to 40% weight loss with semaglutide
Bitget2026/09/23 11:33- Artelo Biosciences filed a provisional patent application covering ART27.13 for obesity as a standalone treatment or with GLP-1 drugs.
- Results were already presented from a nonclinical obese-mouse study, with additional findings disclosed following data released on Sept. 16, 2026.
- ART27.13 showed meaningful weight-loss activity alone, with stronger results when combined with semaglutide.
- The combination also improved metabolic markers and showed a bone-health signal not seen in other study groups.
- The move positions ART27.13 as a potential add-on to GLP-1 therapies, supported by an existing clinical dataset across multiple studies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
